Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Jiangsu Lianhuan Pharmaceutical Co., Ltd. on 6ix
Earlier from Jiangsu Lianhuan Pharmaceutical
- Announcement on Holding Subsidiary Passing Generic Drug Consistency Evaluation
- Announcement on Adding Extraordinary Proposal to the 4th Extraordinary General Meeting in 2025
- Announcement on Amending the Articles of Association, and Formulating and Revising Some Governance Systems
- Announcement on Completion of Change in the Equity Structure of Indirect Shareholders
- Announcement on Active Pharmaceutical Ingredient Levonorgestrel Passing the World Health Organization Prequalification On-site Inspection
Later from Jiangsu Lianhuan Pharmaceutical
- Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
- Announcement on Active Pharmaceutical Ingredient Levonorgestrel Passing the World Health Organization Prequalification
- Announcement on Holding Subsidiary Obtaining Drug Registration Certificate
- Announcement on Obtaining an Approval for Registration of Issued Science and Technology Innovation Bonds
- Announcement on Obtaining Notice of Approval for Clinical Trials of Class 2 Improved New Drug
Follow Jiangsu Lianhuan Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Lianhuan Pharmaceutical